301 related articles for article (PubMed ID: 36902326)
1. The Metabolic Features of Osteoblasts: Implications for Multiple Myeloma (MM) Bone Disease.
Lungu O; Toscani D; Burroughs-Garcia J; Giuliani N
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902326
[TBL] [Abstract][Full Text] [Related]
2. Runx2 Deficiency in Osteoblasts Promotes Myeloma Progression by Altering the Bone Microenvironment at New Bone Sites.
Xu X; Zhang C; Trotter TN; Gowda PS; Lu Y; Ponnazhagan S; Javed A; Li J; Yang Y
Cancer Res; 2020 Mar; 80(5):1036-1048. PubMed ID: 31911552
[TBL] [Abstract][Full Text] [Related]
3. CYR61/CCN1 stimulates proliferation and differentiation of osteoblasts in vitro and contributes to bone remodeling in vivo in myeloma bone disease.
Liu H; Peng F; Liu Z; Jiang F; Li L; Gao S; Wang G; Song J; Ruan E; Shao Z; Fu R
Int J Oncol; 2017 Feb; 50(2):631-639. PubMed ID: 28035364
[TBL] [Abstract][Full Text] [Related]
4. Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2.
Yen CH; Hsu CM; Hsiao SY; Hsiao HH
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937821
[TBL] [Abstract][Full Text] [Related]
5. Role of osteoblast suppression in multiple myeloma.
Stewart JP; Shaughnessy JD
J Cell Biochem; 2006 May; 98(1):1-13. PubMed ID: 16440324
[TBL] [Abstract][Full Text] [Related]
6. N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.
Groen RW; de Rooij MF; Kocemba KA; Reijmers RM; de Haan-Kramer A; Overdijk MB; Aalders L; Rozemuller H; Martens AC; Bergsagel PL; Kersten MJ; Pals ST; Spaargaren M
Haematologica; 2011 Nov; 96(11):1653-61. PubMed ID: 21828122
[TBL] [Abstract][Full Text] [Related]
7. The effects of bortezomib on bone disease in patients with multiple myeloma.
Mohty M; Malard F; Mohty B; Savani B; Moreau P; Terpos E
Cancer; 2014 Mar; 120(5):618-23. PubMed ID: 24249482
[TBL] [Abstract][Full Text] [Related]
8. Osteoblast function in myeloma.
Roodman GD
Bone; 2011 Jan; 48(1):135-40. PubMed ID: 20601285
[TBL] [Abstract][Full Text] [Related]
9. Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth.
Takeuchi K; Abe M; Hiasa M; Oda A; Amou H; Kido S; Harada T; Tanaka O; Miki H; Nakamura S; Nakano A; Kagawa K; Yata K; Ozaki S; Matsumoto T
PLoS One; 2010 Mar; 5(3):e9870. PubMed ID: 20360846
[TBL] [Abstract][Full Text] [Related]
10. Targeting the bone microenvironment in multiple myeloma.
Roodman GD
J Bone Miner Metab; 2010 May; 28(3):244-50. PubMed ID: 20127498
[TBL] [Abstract][Full Text] [Related]
11. Tumor-host cell interactions in the bone disease of myeloma.
Fowler JA; Edwards CM; Croucher PI
Bone; 2011 Jan; 48(1):121-8. PubMed ID: 20615487
[TBL] [Abstract][Full Text] [Related]
12. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
13. Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma.
Lee SE; Min CK; Yahng SA; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Park CW
Eur J Haematol; 2011 Jan; 86(1):83-6. PubMed ID: 20946110
[TBL] [Abstract][Full Text] [Related]
14. Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease.
Eda H; Santo L; Wein MN; Hu DZ; Cirstea DD; Nemani N; Tai YT; Raines SE; Kuhstoss SA; Munshi NC; Kronenberg HM; Raje NS
J Bone Miner Res; 2016 Jun; 31(6):1225-34. PubMed ID: 26763740
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen/plasmin modulates bone metabolism by regulating the osteoblast and osteoclast function.
Kanno Y; Ishisaki A; Kawashita E; Chosa N; Nakajima K; Nishihara T; Toyoshima K; Okada K; Ueshima S; Matsushita K; Matsuo O; Matsuno H
J Biol Chem; 2011 Mar; 286(11):8952-60. PubMed ID: 21239499
[TBL] [Abstract][Full Text] [Related]
16. Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease.
Todoerti K; Lisignoli G; Storti P; Agnelli L; Novara F; Manferdini C; Codeluppi K; Colla S; Crugnola M; Abeltino M; Bolzoni M; Sgobba V; Facchini A; Lambertenghi-Deliliers G; Zuffardi O; Rizzoli V; Neri A; Giuliani N
Exp Hematol; 2010 Feb; 38(2):141-53. PubMed ID: 19963035
[TBL] [Abstract][Full Text] [Related]
17. Bioenergetic Metabolism In Osteoblast Differentiation.
Shen L; Hu G; Karner CM
Curr Osteoporos Rep; 2022 Feb; 20(1):53-64. PubMed ID: 35112289
[TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis.
Raimondo S; Saieva L; Vicario E; Pucci M; Toscani D; Manno M; Raccosta S; Giuliani N; Alessandro R
J Hematol Oncol; 2019 Jan; 12(1):2. PubMed ID: 30621731
[TBL] [Abstract][Full Text] [Related]
19. Human myeloma cell lines induce osteoblast downregulation of CD99 which is involved in osteoblast formation and activity.
Oranger A; Brunetti G; Carbone C; Colaianni G; Mongelli T; Gigante I; Tamma R; Mori G; Di Benedetto A; Sciandra M; Ventura S; Scotlandi K; Colucci S; Grano M
J Immunol Res; 2015; 2015():156787. PubMed ID: 26000312
[TBL] [Abstract][Full Text] [Related]
20. TIEG1 null mouse-derived osteoblasts are defective in mineralization and in support of osteoclast differentiation in vitro.
Subramaniam M; Gorny G; Johnsen SA; Monroe DG; Evans GL; Fraser DG; Rickard DJ; Rasmussen K; van Deursen JM; Turner RT; Oursler MJ; Spelsberg TC
Mol Cell Biol; 2005 Feb; 25(3):1191-9. PubMed ID: 15657444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
